** Casi Pharmaceuticals' shares fall 14.89% to $2.40 premarket
** Co says its application to start trials for its experimental antibody in patients with a type of complication related to kidney transplants was placed on clinical hold
** The complication, known as Antibody Mediated Rejection, occurs after a transplant when the recipient's immune system produces antibodies that attack the transplanted organ
** Co's application supporting early-to-mid stage trial of the antibody in adults with chronic immune thrombocytopenia, a rare autoimmune blood disorder, remains open
** Up to last close, stock down ~60% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。